nodes	percent_of_prediction	percent_of_DWPC	metapath
Glycopyrrolate—Oedema—Vincristine—sarcoma	0.003	0.003	CcSEcCtD
Glycopyrrolate—Infection—Vincristine—sarcoma	0.00298	0.00298	CcSEcCtD
Glycopyrrolate—Dyspepsia—Thiotepa—sarcoma	0.00298	0.00298	CcSEcCtD
Glycopyrrolate—Confusional state—Mitoxantrone—sarcoma	0.00295	0.00295	CcSEcCtD
Glycopyrrolate—Nervous system disorder—Vincristine—sarcoma	0.00295	0.00295	CcSEcCtD
Glycopyrrolate—Oedema—Mitoxantrone—sarcoma	0.00293	0.00293	CcSEcCtD
Glycopyrrolate—Anaphylactic shock—Mitoxantrone—sarcoma	0.00293	0.00293	CcSEcCtD
Glycopyrrolate—Gastrointestinal disorder—Thiotepa—sarcoma	0.00293	0.00293	CcSEcCtD
Glycopyrrolate—Fatigue—Thiotepa—sarcoma	0.00292	0.00292	CcSEcCtD
Glycopyrrolate—Dysgeusia—Etoposide—sarcoma	0.00292	0.00292	CcSEcCtD
Glycopyrrolate—Infection—Mitoxantrone—sarcoma	0.00291	0.00291	CcSEcCtD
Glycopyrrolate—Hyperhidrosis—Vincristine—sarcoma	0.0029	0.0029	CcSEcCtD
Glycopyrrolate—Fatigue—Dactinomycin—sarcoma	0.0029	0.0029	CcSEcCtD
Glycopyrrolate—Constipation—Thiotepa—sarcoma	0.0029	0.0029	CcSEcCtD
Glycopyrrolate—Pain—Thiotepa—sarcoma	0.0029	0.0029	CcSEcCtD
Glycopyrrolate—Pain—Dactinomycin—sarcoma	0.00288	0.00288	CcSEcCtD
Glycopyrrolate—Anaphylactoid reaction—Epirubicin—sarcoma	0.00287	0.00287	CcSEcCtD
Glycopyrrolate—Tachycardia—Mitoxantrone—sarcoma	0.00286	0.00286	CcSEcCtD
Glycopyrrolate—Skin disorder—Mitoxantrone—sarcoma	0.00284	0.00284	CcSEcCtD
Glycopyrrolate—Hyperhidrosis—Mitoxantrone—sarcoma	0.00283	0.00283	CcSEcCtD
Glycopyrrolate—Hypotension—Vincristine—sarcoma	0.00281	0.00281	CcSEcCtD
Glycopyrrolate—Feeling abnormal—Thiotepa—sarcoma	0.00279	0.00279	CcSEcCtD
Glycopyrrolate—Pain in extremity—Epirubicin—sarcoma	0.00278	0.00278	CcSEcCtD
Glycopyrrolate—Feeling abnormal—Dactinomycin—sarcoma	0.00277	0.00277	CcSEcCtD
Glycopyrrolate—Gastrointestinal pain—Thiotepa—sarcoma	0.00277	0.00277	CcSEcCtD
Glycopyrrolate—Gastrointestinal pain—Dactinomycin—sarcoma	0.00275	0.00275	CcSEcCtD
Glycopyrrolate—Hypotension—Mitoxantrone—sarcoma	0.00273	0.00273	CcSEcCtD
Glycopyrrolate—Affect lability—Epirubicin—sarcoma	0.00273	0.00273	CcSEcCtD
Glycopyrrolate—Insomnia—Vincristine—sarcoma	0.00272	0.00272	CcSEcCtD
Glycopyrrolate—Urticaria—Thiotepa—sarcoma	0.00269	0.00269	CcSEcCtD
Glycopyrrolate—Abdominal pain—Thiotepa—sarcoma	0.00268	0.00268	CcSEcCtD
Glycopyrrolate—Body temperature increased—Thiotepa—sarcoma	0.00268	0.00268	CcSEcCtD
Glycopyrrolate—Abdominal pain—Dactinomycin—sarcoma	0.00266	0.00266	CcSEcCtD
Glycopyrrolate—Body temperature increased—Dactinomycin—sarcoma	0.00266	0.00266	CcSEcCtD
Glycopyrrolate—Anaphylactoid reaction—Doxorubicin—sarcoma	0.00265	0.00265	CcSEcCtD
Glycopyrrolate—Cardiac arrest—Epirubicin—sarcoma	0.00264	0.00264	CcSEcCtD
Glycopyrrolate—Mood swings—Epirubicin—sarcoma	0.00263	0.00263	CcSEcCtD
Glycopyrrolate—Somnolence—Mitoxantrone—sarcoma	0.0026	0.0026	CcSEcCtD
Glycopyrrolate—Gastrointestinal disorder—Vincristine—sarcoma	0.00259	0.00259	CcSEcCtD
Glycopyrrolate—Fatigue—Vincristine—sarcoma	0.00259	0.00259	CcSEcCtD
Glycopyrrolate—Convulsion—Etoposide—sarcoma	0.00258	0.00258	CcSEcCtD
Glycopyrrolate—Dehydration—Epirubicin—sarcoma	0.00258	0.00258	CcSEcCtD
Glycopyrrolate—Dyspepsia—Mitoxantrone—sarcoma	0.00258	0.00258	CcSEcCtD
Glycopyrrolate—Hypertension—Etoposide—sarcoma	0.00257	0.00257	CcSEcCtD
Glycopyrrolate—Constipation—Vincristine—sarcoma	0.00257	0.00257	CcSEcCtD
Glycopyrrolate—Pain—Vincristine—sarcoma	0.00257	0.00257	CcSEcCtD
Glycopyrrolate—Pain in extremity—Doxorubicin—sarcoma	0.00257	0.00257	CcSEcCtD
Glycopyrrolate—Dry skin—Epirubicin—sarcoma	0.00254	0.00254	CcSEcCtD
Glycopyrrolate—Affect lability—Doxorubicin—sarcoma	0.00253	0.00253	CcSEcCtD
Glycopyrrolate—Fatigue—Mitoxantrone—sarcoma	0.00252	0.00252	CcSEcCtD
Glycopyrrolate—Unspecified disorder of skin and subcutaneous tissue—Etoposide—sarcoma	0.00252	0.00252	CcSEcCtD
Glycopyrrolate—Pain—Mitoxantrone—sarcoma	0.0025	0.0025	CcSEcCtD
Glycopyrrolate—Constipation—Mitoxantrone—sarcoma	0.0025	0.0025	CcSEcCtD
Glycopyrrolate—Hypersensitivity—Thiotepa—sarcoma	0.0025	0.0025	CcSEcCtD
Glycopyrrolate—Nasopharyngitis—Epirubicin—sarcoma	0.00248	0.00248	CcSEcCtD
Glycopyrrolate—Hypersensitivity—Dactinomycin—sarcoma	0.00248	0.00248	CcSEcCtD
Glycopyrrolate—Gastrointestinal pain—Vincristine—sarcoma	0.00246	0.00246	CcSEcCtD
Glycopyrrolate—Confusional state—Etoposide—sarcoma	0.00245	0.00245	CcSEcCtD
Glycopyrrolate—Cardiac arrest—Doxorubicin—sarcoma	0.00244	0.00244	CcSEcCtD
Glycopyrrolate—Anaphylactic shock—Etoposide—sarcoma	0.00243	0.00243	CcSEcCtD
Glycopyrrolate—Mood swings—Doxorubicin—sarcoma	0.00243	0.00243	CcSEcCtD
Glycopyrrolate—Asthenia—Thiotepa—sarcoma	0.00243	0.00243	CcSEcCtD
Glycopyrrolate—Infection—Etoposide—sarcoma	0.00242	0.00242	CcSEcCtD
Glycopyrrolate—Abdominal distension—Epirubicin—sarcoma	0.00242	0.00242	CcSEcCtD
Glycopyrrolate—Asthenia—Dactinomycin—sarcoma	0.00241	0.00241	CcSEcCtD
Glycopyrrolate—Feeling abnormal—Mitoxantrone—sarcoma	0.00241	0.00241	CcSEcCtD
Glycopyrrolate—Pruritus—Thiotepa—sarcoma	0.0024	0.0024	CcSEcCtD
Glycopyrrolate—Gastrointestinal pain—Mitoxantrone—sarcoma	0.00239	0.00239	CcSEcCtD
Glycopyrrolate—Dehydration—Doxorubicin—sarcoma	0.00239	0.00239	CcSEcCtD
Glycopyrrolate—Tachycardia—Etoposide—sarcoma	0.00238	0.00238	CcSEcCtD
Glycopyrrolate—Abdominal pain—Vincristine—sarcoma	0.00237	0.00237	CcSEcCtD
Glycopyrrolate—Body temperature increased—Vincristine—sarcoma	0.00237	0.00237	CcSEcCtD
Glycopyrrolate—Skin disorder—Etoposide—sarcoma	0.00236	0.00236	CcSEcCtD
Glycopyrrolate—Dry skin—Doxorubicin—sarcoma	0.00235	0.00235	CcSEcCtD
Glycopyrrolate—Hyperhidrosis—Etoposide—sarcoma	0.00235	0.00235	CcSEcCtD
Glycopyrrolate—Urticaria—Mitoxantrone—sarcoma	0.00232	0.00232	CcSEcCtD
Glycopyrrolate—Body temperature increased—Mitoxantrone—sarcoma	0.00231	0.00231	CcSEcCtD
Glycopyrrolate—Abdominal pain—Mitoxantrone—sarcoma	0.00231	0.00231	CcSEcCtD
Glycopyrrolate—Nasopharyngitis—Doxorubicin—sarcoma	0.0023	0.0023	CcSEcCtD
Glycopyrrolate—Hypotension—Etoposide—sarcoma	0.00227	0.00227	CcSEcCtD
Glycopyrrolate—Dysuria—Epirubicin—sarcoma	0.00224	0.00224	CcSEcCtD
Glycopyrrolate—Dizziness—Thiotepa—sarcoma	0.00224	0.00224	CcSEcCtD
Glycopyrrolate—Abdominal distension—Doxorubicin—sarcoma	0.00223	0.00223	CcSEcCtD
Glycopyrrolate—Upper respiratory tract infection—Epirubicin—sarcoma	0.00223	0.00223	CcSEcCtD
Glycopyrrolate—Hypersensitivity—Vincristine—sarcoma	0.00221	0.00221	CcSEcCtD
Glycopyrrolate—Hyperglycaemia—Epirubicin—sarcoma	0.00216	0.00216	CcSEcCtD
Glycopyrrolate—Somnolence—Etoposide—sarcoma	0.00216	0.00216	CcSEcCtD
Glycopyrrolate—Hypersensitivity—Mitoxantrone—sarcoma	0.00216	0.00216	CcSEcCtD
Glycopyrrolate—Asthenia—Vincristine—sarcoma	0.00216	0.00216	CcSEcCtD
Glycopyrrolate—Vomiting—Thiotepa—sarcoma	0.00215	0.00215	CcSEcCtD
Glycopyrrolate—Pneumonia—Epirubicin—sarcoma	0.00215	0.00215	CcSEcCtD
Glycopyrrolate—Drowsiness—Epirubicin—sarcoma	0.00214	0.00214	CcSEcCtD
Glycopyrrolate—Infestation—Epirubicin—sarcoma	0.00214	0.00214	CcSEcCtD
Glycopyrrolate—Infestation NOS—Epirubicin—sarcoma	0.00214	0.00214	CcSEcCtD
Glycopyrrolate—Vomiting—Dactinomycin—sarcoma	0.00214	0.00214	CcSEcCtD
Glycopyrrolate—Rash—Thiotepa—sarcoma	0.00214	0.00214	CcSEcCtD
Glycopyrrolate—Dermatitis—Thiotepa—sarcoma	0.00213	0.00213	CcSEcCtD
Glycopyrrolate—Headache—Thiotepa—sarcoma	0.00212	0.00212	CcSEcCtD
Glycopyrrolate—Rash—Dactinomycin—sarcoma	0.00212	0.00212	CcSEcCtD
Glycopyrrolate—Gastrointestinal disorder—Etoposide—sarcoma	0.0021	0.0021	CcSEcCtD
Glycopyrrolate—Asthenia—Mitoxantrone—sarcoma	0.0021	0.0021	CcSEcCtD
Glycopyrrolate—Fatigue—Etoposide—sarcoma	0.0021	0.0021	CcSEcCtD
Glycopyrrolate—Pain—Etoposide—sarcoma	0.00208	0.00208	CcSEcCtD
Glycopyrrolate—Constipation—Etoposide—sarcoma	0.00208	0.00208	CcSEcCtD
Glycopyrrolate—Urinary tract infection—Epirubicin—sarcoma	0.00208	0.00208	CcSEcCtD
Glycopyrrolate—Dysuria—Doxorubicin—sarcoma	0.00208	0.00208	CcSEcCtD
Glycopyrrolate—Upper respiratory tract infection—Doxorubicin—sarcoma	0.00206	0.00206	CcSEcCtD
Glycopyrrolate—Sweating—Epirubicin—sarcoma	0.00205	0.00205	CcSEcCtD
Glycopyrrolate—Epistaxis—Epirubicin—sarcoma	0.00202	0.00202	CcSEcCtD
Glycopyrrolate—Nausea—Thiotepa—sarcoma	0.00201	0.00201	CcSEcCtD
Glycopyrrolate—Sinusitis—Epirubicin—sarcoma	0.00201	0.00201	CcSEcCtD
Glycopyrrolate—Feeling abnormal—Etoposide—sarcoma	0.00201	0.00201	CcSEcCtD
Glycopyrrolate—Hyperglycaemia—Doxorubicin—sarcoma	0.002	0.002	CcSEcCtD
Glycopyrrolate—Nausea—Dactinomycin—sarcoma	0.002	0.002	CcSEcCtD
Glycopyrrolate—Pneumonia—Doxorubicin—sarcoma	0.00199	0.00199	CcSEcCtD
Glycopyrrolate—Gastrointestinal pain—Etoposide—sarcoma	0.00199	0.00199	CcSEcCtD
Glycopyrrolate—Dizziness—Vincristine—sarcoma	0.00199	0.00199	CcSEcCtD
Glycopyrrolate—Infestation NOS—Doxorubicin—sarcoma	0.00198	0.00198	CcSEcCtD
Glycopyrrolate—Drowsiness—Doxorubicin—sarcoma	0.00198	0.00198	CcSEcCtD
Glycopyrrolate—Infestation—Doxorubicin—sarcoma	0.00198	0.00198	CcSEcCtD
Glycopyrrolate—Urticaria—Etoposide—sarcoma	0.00193	0.00193	CcSEcCtD
Glycopyrrolate—Rhinitis—Epirubicin—sarcoma	0.00193	0.00193	CcSEcCtD
Glycopyrrolate—Body temperature increased—Etoposide—sarcoma	0.00192	0.00192	CcSEcCtD
Glycopyrrolate—Abdominal pain—Etoposide—sarcoma	0.00192	0.00192	CcSEcCtD
Glycopyrrolate—Urinary tract infection—Doxorubicin—sarcoma	0.00192	0.00192	CcSEcCtD
Glycopyrrolate—Hypoaesthesia—Epirubicin—sarcoma	0.00191	0.00191	CcSEcCtD
Glycopyrrolate—Vomiting—Vincristine—sarcoma	0.00191	0.00191	CcSEcCtD
Glycopyrrolate—Sweating—Doxorubicin—sarcoma	0.0019	0.0019	CcSEcCtD
Glycopyrrolate—Urinary tract disorder—Epirubicin—sarcoma	0.0019	0.0019	CcSEcCtD
Glycopyrrolate—Rash—Vincristine—sarcoma	0.00189	0.00189	CcSEcCtD
Glycopyrrolate—Dermatitis—Vincristine—sarcoma	0.00189	0.00189	CcSEcCtD
Glycopyrrolate—Connective tissue disorder—Epirubicin—sarcoma	0.00189	0.00189	CcSEcCtD
Glycopyrrolate—Urethral disorder—Epirubicin—sarcoma	0.00188	0.00188	CcSEcCtD
Glycopyrrolate—Headache—Vincristine—sarcoma	0.00188	0.00188	CcSEcCtD
Glycopyrrolate—Epistaxis—Doxorubicin—sarcoma	0.00187	0.00187	CcSEcCtD
Glycopyrrolate—Vomiting—Mitoxantrone—sarcoma	0.00186	0.00186	CcSEcCtD
Glycopyrrolate—Sinusitis—Doxorubicin—sarcoma	0.00186	0.00186	CcSEcCtD
Glycopyrrolate—Rash—Mitoxantrone—sarcoma	0.00184	0.00184	CcSEcCtD
Glycopyrrolate—Dermatitis—Mitoxantrone—sarcoma	0.00184	0.00184	CcSEcCtD
Glycopyrrolate—Headache—Mitoxantrone—sarcoma	0.00183	0.00183	CcSEcCtD
Glycopyrrolate—Hypersensitivity—Etoposide—sarcoma	0.00179	0.00179	CcSEcCtD
Glycopyrrolate—Nausea—Vincristine—sarcoma	0.00178	0.00178	CcSEcCtD
Glycopyrrolate—Flushing—Epirubicin—sarcoma	0.00178	0.00178	CcSEcCtD
Glycopyrrolate—Cardiac disorder—Epirubicin—sarcoma	0.00178	0.00178	CcSEcCtD
Glycopyrrolate—Rhinitis—Doxorubicin—sarcoma	0.00178	0.00178	CcSEcCtD
Glycopyrrolate—Hypoaesthesia—Doxorubicin—sarcoma	0.00177	0.00177	CcSEcCtD
Glycopyrrolate—Urinary tract disorder—Doxorubicin—sarcoma	0.00175	0.00175	CcSEcCtD
Glycopyrrolate—Asthenia—Etoposide—sarcoma	0.00175	0.00175	CcSEcCtD
Glycopyrrolate—Connective tissue disorder—Doxorubicin—sarcoma	0.00175	0.00175	CcSEcCtD
Glycopyrrolate—Urethral disorder—Doxorubicin—sarcoma	0.00174	0.00174	CcSEcCtD
Glycopyrrolate—Nausea—Mitoxantrone—sarcoma	0.00174	0.00174	CcSEcCtD
Glycopyrrolate—Mediastinal disorder—Epirubicin—sarcoma	0.00173	0.00173	CcSEcCtD
Glycopyrrolate—Pruritus—Etoposide—sarcoma	0.00172	0.00172	CcSEcCtD
Glycopyrrolate—Mental disorder—Epirubicin—sarcoma	0.00168	0.00168	CcSEcCtD
Glycopyrrolate—Malnutrition—Epirubicin—sarcoma	0.00167	0.00167	CcSEcCtD
Glycopyrrolate—Erythema—Epirubicin—sarcoma	0.00167	0.00167	CcSEcCtD
Glycopyrrolate—Flushing—Doxorubicin—sarcoma	0.00165	0.00165	CcSEcCtD
Glycopyrrolate—Cardiac disorder—Doxorubicin—sarcoma	0.00165	0.00165	CcSEcCtD
Glycopyrrolate—Flatulence—Epirubicin—sarcoma	0.00165	0.00165	CcSEcCtD
Glycopyrrolate—Tension—Epirubicin—sarcoma	0.00164	0.00164	CcSEcCtD
Glycopyrrolate—Dysgeusia—Epirubicin—sarcoma	0.00164	0.00164	CcSEcCtD
Glycopyrrolate—Nervousness—Epirubicin—sarcoma	0.00162	0.00162	CcSEcCtD
Glycopyrrolate—Dizziness—Etoposide—sarcoma	0.00161	0.00161	CcSEcCtD
Glycopyrrolate—Mediastinal disorder—Doxorubicin—sarcoma	0.0016	0.0016	CcSEcCtD
Glycopyrrolate—Vision blurred—Epirubicin—sarcoma	0.00158	0.00158	CcSEcCtD
Glycopyrrolate—Mental disorder—Doxorubicin—sarcoma	0.00156	0.00156	CcSEcCtD
Glycopyrrolate—Vomiting—Etoposide—sarcoma	0.00155	0.00155	CcSEcCtD
Glycopyrrolate—Malnutrition—Doxorubicin—sarcoma	0.00155	0.00155	CcSEcCtD
Glycopyrrolate—Erythema—Doxorubicin—sarcoma	0.00155	0.00155	CcSEcCtD
Glycopyrrolate—Agitation—Epirubicin—sarcoma	0.00154	0.00154	CcSEcCtD
Glycopyrrolate—Rash—Etoposide—sarcoma	0.00153	0.00153	CcSEcCtD
Glycopyrrolate—Dermatitis—Etoposide—sarcoma	0.00153	0.00153	CcSEcCtD
Glycopyrrolate—Headache—Etoposide—sarcoma	0.00152	0.00152	CcSEcCtD
Glycopyrrolate—Flatulence—Doxorubicin—sarcoma	0.00152	0.00152	CcSEcCtD
Glycopyrrolate—Tension—Doxorubicin—sarcoma	0.00152	0.00152	CcSEcCtD
Glycopyrrolate—Dysgeusia—Doxorubicin—sarcoma	0.00151	0.00151	CcSEcCtD
Glycopyrrolate—Nervousness—Doxorubicin—sarcoma	0.0015	0.0015	CcSEcCtD
Glycopyrrolate—Palpitations—Epirubicin—sarcoma	0.00148	0.00148	CcSEcCtD
Glycopyrrolate—Vision blurred—Doxorubicin—sarcoma	0.00146	0.00146	CcSEcCtD
Glycopyrrolate—Convulsion—Epirubicin—sarcoma	0.00145	0.00145	CcSEcCtD
Glycopyrrolate—Nausea—Etoposide—sarcoma	0.00145	0.00145	CcSEcCtD
Glycopyrrolate—Hypertension—Epirubicin—sarcoma	0.00144	0.00144	CcSEcCtD
Glycopyrrolate—Agitation—Doxorubicin—sarcoma	0.00142	0.00142	CcSEcCtD
Glycopyrrolate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—sarcoma	0.00141	0.00141	CcSEcCtD
Glycopyrrolate—Dry mouth—Epirubicin—sarcoma	0.00139	0.00139	CcSEcCtD
Glycopyrrolate—Confusional state—Epirubicin—sarcoma	0.00138	0.00138	CcSEcCtD
Glycopyrrolate—Palpitations—Doxorubicin—sarcoma	0.00137	0.00137	CcSEcCtD
Glycopyrrolate—Oedema—Epirubicin—sarcoma	0.00136	0.00136	CcSEcCtD
Glycopyrrolate—Anaphylactic shock—Epirubicin—sarcoma	0.00136	0.00136	CcSEcCtD
Glycopyrrolate—Infection—Epirubicin—sarcoma	0.00136	0.00136	CcSEcCtD
Glycopyrrolate—Convulsion—Doxorubicin—sarcoma	0.00134	0.00134	CcSEcCtD
Glycopyrrolate—Nervous system disorder—Epirubicin—sarcoma	0.00134	0.00134	CcSEcCtD
Glycopyrrolate—Hypertension—Doxorubicin—sarcoma	0.00134	0.00134	CcSEcCtD
Glycopyrrolate—Tachycardia—Epirubicin—sarcoma	0.00133	0.00133	CcSEcCtD
Glycopyrrolate—Skin disorder—Epirubicin—sarcoma	0.00133	0.00133	CcSEcCtD
Glycopyrrolate—Hyperhidrosis—Epirubicin—sarcoma	0.00132	0.00132	CcSEcCtD
Glycopyrrolate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—sarcoma	0.00131	0.00131	CcSEcCtD
Glycopyrrolate—Dry mouth—Doxorubicin—sarcoma	0.00129	0.00129	CcSEcCtD
Glycopyrrolate—Hypotension—Epirubicin—sarcoma	0.00127	0.00127	CcSEcCtD
Glycopyrrolate—Confusional state—Doxorubicin—sarcoma	0.00127	0.00127	CcSEcCtD
Glycopyrrolate—Anaphylactic shock—Doxorubicin—sarcoma	0.00126	0.00126	CcSEcCtD
Glycopyrrolate—Oedema—Doxorubicin—sarcoma	0.00126	0.00126	CcSEcCtD
Glycopyrrolate—Infection—Doxorubicin—sarcoma	0.00125	0.00125	CcSEcCtD
Glycopyrrolate—Nervous system disorder—Doxorubicin—sarcoma	0.00124	0.00124	CcSEcCtD
Glycopyrrolate—Insomnia—Epirubicin—sarcoma	0.00123	0.00123	CcSEcCtD
Glycopyrrolate—Tachycardia—Doxorubicin—sarcoma	0.00123	0.00123	CcSEcCtD
Glycopyrrolate—Skin disorder—Doxorubicin—sarcoma	0.00123	0.00123	CcSEcCtD
Glycopyrrolate—Hyperhidrosis—Doxorubicin—sarcoma	0.00122	0.00122	CcSEcCtD
Glycopyrrolate—Somnolence—Epirubicin—sarcoma	0.00121	0.00121	CcSEcCtD
Glycopyrrolate—Dyspepsia—Epirubicin—sarcoma	0.0012	0.0012	CcSEcCtD
Glycopyrrolate—Hypotension—Doxorubicin—sarcoma	0.00118	0.00118	CcSEcCtD
Glycopyrrolate—Gastrointestinal disorder—Epirubicin—sarcoma	0.00118	0.00118	CcSEcCtD
Glycopyrrolate—Fatigue—Epirubicin—sarcoma	0.00118	0.00118	CcSEcCtD
Glycopyrrolate—Constipation—Epirubicin—sarcoma	0.00117	0.00117	CcSEcCtD
Glycopyrrolate—Pain—Epirubicin—sarcoma	0.00117	0.00117	CcSEcCtD
Glycopyrrolate—Insomnia—Doxorubicin—sarcoma	0.00114	0.00114	CcSEcCtD
Glycopyrrolate—Feeling abnormal—Epirubicin—sarcoma	0.00112	0.00112	CcSEcCtD
Glycopyrrolate—Somnolence—Doxorubicin—sarcoma	0.00112	0.00112	CcSEcCtD
Glycopyrrolate—Gastrointestinal pain—Epirubicin—sarcoma	0.00112	0.00112	CcSEcCtD
Glycopyrrolate—Dyspepsia—Doxorubicin—sarcoma	0.00111	0.00111	CcSEcCtD
Glycopyrrolate—Gastrointestinal disorder—Doxorubicin—sarcoma	0.00109	0.00109	CcSEcCtD
Glycopyrrolate—Fatigue—Doxorubicin—sarcoma	0.00109	0.00109	CcSEcCtD
Glycopyrrolate—Urticaria—Epirubicin—sarcoma	0.00108	0.00108	CcSEcCtD
Glycopyrrolate—Constipation—Doxorubicin—sarcoma	0.00108	0.00108	CcSEcCtD
Glycopyrrolate—Pain—Doxorubicin—sarcoma	0.00108	0.00108	CcSEcCtD
Glycopyrrolate—Abdominal pain—Epirubicin—sarcoma	0.00108	0.00108	CcSEcCtD
Glycopyrrolate—Body temperature increased—Epirubicin—sarcoma	0.00108	0.00108	CcSEcCtD
Glycopyrrolate—Feeling abnormal—Doxorubicin—sarcoma	0.00104	0.00104	CcSEcCtD
Glycopyrrolate—Gastrointestinal pain—Doxorubicin—sarcoma	0.00103	0.00103	CcSEcCtD
Glycopyrrolate—Hypersensitivity—Epirubicin—sarcoma	0.00101	0.00101	CcSEcCtD
Glycopyrrolate—Urticaria—Doxorubicin—sarcoma	0.001	0.001	CcSEcCtD
Glycopyrrolate—Abdominal pain—Doxorubicin—sarcoma	0.000998	0.000998	CcSEcCtD
Glycopyrrolate—Body temperature increased—Doxorubicin—sarcoma	0.000998	0.000998	CcSEcCtD
Glycopyrrolate—Asthenia—Epirubicin—sarcoma	0.000979	0.000979	CcSEcCtD
Glycopyrrolate—Pruritus—Epirubicin—sarcoma	0.000965	0.000965	CcSEcCtD
Glycopyrrolate—Hypersensitivity—Doxorubicin—sarcoma	0.00093	0.00093	CcSEcCtD
Glycopyrrolate—Asthenia—Doxorubicin—sarcoma	0.000906	0.000906	CcSEcCtD
Glycopyrrolate—Dizziness—Epirubicin—sarcoma	0.000902	0.000902	CcSEcCtD
Glycopyrrolate—Pruritus—Doxorubicin—sarcoma	0.000893	0.000893	CcSEcCtD
Glycopyrrolate—Vomiting—Epirubicin—sarcoma	0.000867	0.000867	CcSEcCtD
Glycopyrrolate—Rash—Epirubicin—sarcoma	0.00086	0.00086	CcSEcCtD
Glycopyrrolate—Dermatitis—Epirubicin—sarcoma	0.000859	0.000859	CcSEcCtD
Glycopyrrolate—Headache—Epirubicin—sarcoma	0.000855	0.000855	CcSEcCtD
Glycopyrrolate—Dizziness—Doxorubicin—sarcoma	0.000835	0.000835	CcSEcCtD
Glycopyrrolate—Nausea—Epirubicin—sarcoma	0.00081	0.00081	CcSEcCtD
Glycopyrrolate—Vomiting—Doxorubicin—sarcoma	0.000803	0.000803	CcSEcCtD
Glycopyrrolate—Rash—Doxorubicin—sarcoma	0.000796	0.000796	CcSEcCtD
Glycopyrrolate—Dermatitis—Doxorubicin—sarcoma	0.000795	0.000795	CcSEcCtD
Glycopyrrolate—Headache—Doxorubicin—sarcoma	0.000791	0.000791	CcSEcCtD
Glycopyrrolate—Nausea—Doxorubicin—sarcoma	0.00075	0.00075	CcSEcCtD
